In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir

• Published in: Nature communications Vol. 14; no. 1; pp. 4231 - 8
• Main Authors: Kiso, Maki, Yamayoshi, Seiya, Iida, Shun, Furusawa, Yuri, Hirata, Yuichiro, Uraki, Ryuta, Imai, Masaki, Suzuki, Tadaki, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 15.07.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 13/51; 631/326/22/1295; 631/326/596/4130; Animals; Antiviral agents; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Antiviral drugs; COVID-19; Cricetinae; Hamsters; Humanities and Social Sciences; Immunotherapy; Monoclonal antibodies; multidisciplinary; Pathogenicity; Pathogens; Protease; Protease inhibitors; Proteinase inhibitors; Public health; SARS-CoV-2; Science; Science (multidisciplinary); Sensitivity; Severe acute respiratory syndrome coronavirus 2; Viral diseases; Viruses

Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most omicron subvariants have reduced sensitivity to most monoclonal antibody therapies, SARS-CoV-2 resistance to other antivir...